Pharmaguy's Insights Into Drug Industry News
186.0K views | +14 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Rescooped by Pharma Guy from New pharma
Scoop.it!

Pharma reputation from a patient perspective is growing! See the latest results of 2015 survey.

Pharma reputation from a patient perspective is growing! See the latest results of 2015 survey. | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Reports published in 2016 on the Corporate Reputation of Pharma, as viewed by over 1,000 patient groups

 

The corporate Reputation of Pharma is growing:
In 2011 there was 42.0% of patient groups stating that the corporate reputation of the Pharma industry is "excellent" or "good". Although this percentage decreased to a 34% in 2012, it has increased ever since to 44.7% in 2015!

For a quick summary about our methodology and series of reports on corporate reputation of pharma and medical devices view the powerpoint here

 

Of course, this global indicators must be seen from the differentiated perspectives of regions and diseases!

 

Reports of Pharma's Corporate Reputation over regions:

GLOBAL, EUROPE and EASTERN Europe; GERMANY, ITALY, NORDIC, LATIN AMERICA, SPAIN, UK & USA

 

Reports of Pharma's Corporate Reputation over therapeutic areas.:

Cancer; Circulatory conditions; Diabetes; HIV/Aids; Hepatitis; Neurological conditions; Mental health; Skin; Respiratory and Rare diseases.
Reports for Respiratory and Circulatory conditions are forthcoming. 


Via rob halkes
Pharma Guy's insight:

Related article: “Pharma's Rep Among Patient Groups at 4-Year High”; http://sco.lt/6eoNgf It should be noted that several of the patient organizations participating in this survey receive funding from the pharmaceutical industry. Also read, “#Pharma to Patient Advocacy Groups Questioning High Drug Prices: ‘Why Are You Doing This to Us?’”; http://sco.lt/4sOB7J and “Americans Hate the #Pharma Industry Almost as Much as They Hate U.S. Gov't!”; http://sco.lt/7K6aLB

more...
rob halkes's curator insight, October 18, 2016 5:50 AM

Great to seen how pharma's Corporate Reputation in the eyes of the patients is growing globally from 2011 to 2015, with a dip in 2012. Study the nuances for different global regions and Disease conditions!

Scooped by Pharma Guy
Scoop.it!

Today is World Hepatitis Day: Access to New Treatments for Hep C Difficult, Says WHO

Today is World Hepatitis Day: Access to New Treatments for Hep C Difficult, Says WHO | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Every year on 28 July, WHO and partners mark World Hepatitis Day to increase the awareness and understanding of viral hepatitis and the diseases that it causes.

Viral hepatitis – a group of infectious diseases known as Hepatitis A, B, C, D, and E – affects hundreds of millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year. But hepatitis remains largely ignored or unknown.


In April this year, WHO issued new recommendations on treatment of Hepatitis C. In May, World Health Assembly delegates from 194 governments adopted a resolution to improve prevention, diagnosis, and treatment of viral hepatitis.


On World Hepatitis Day, 28 July 2014, WHO and partners will urge policymakers, health workers and the public to 'Think again' about this silent killer.


World Hepatitis Day provides an opportunity to focus on specific actions, such as:


  • strengthening prevention, screening and control of viral hepatitis and its related diseases;
  • increasing hepatitis B vaccine coverage and integration of the vaccine into national immunization programmes;
  • coordinating a global response to viral hepatitis.


The date of 28 July was chosen for World Hepatitis Day in honour of the birthday of Nobel Laureate Professor Baruch Samuel Blumberg, discoverer of the hepatitis B virus.

Pharma Guy's insight:


From the Hep C Fact Sheet:


Scientific advances have led to the development of new antiviral drugs for hepatitis C, which are much more effective, safer and better-tolerated than existing therapies. These therapies, known as oral directly acting antiviral agent (DAAs) therapies simplify hepatitis C treatment by significantly decreasing monitoring requirements and by increasing cure rates. Although the production cost of DAAs is low, the initial prices set by companies are very high and likely to make access to these drugs difficult even in high-income countries.

more...
No comment yet.